+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Eosinophilic Esophagitis Drug Market Share, Size, Trends, Industry Analysis Report, By Product; By Diagnosis; By Treatment; By Regions; Segment Forecast, 2021-2028

  • ID: 5261964
  • Report
  • January 2021
  • Region: Global
  • 111 pages
  • Polaris Market Research

FEATURED COMPANIES

  • Allakos Inc.
  • Arena Pharmaceuticals
  • Bristol-Myers Squibb
  • Ception Therapeutics
  • DBV Technologies
  • Dr. Falk Pharma GmbH
The global eosinophilic esophagitis drug market size is expected to reach US$ 189.7 million by 2028, according to the study.

The report “Eosinophilic Esophagitis Drug Market Share, Size, Trends, Industry Analysis Report, By Product (Off-Label Drugs, Budesonide Oral Suspension, Fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and Losartan); By Diagnosis; By Treatment; By Regions; Segment Forecast, 2021-2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The market for eosinophilic esophagitis drug is driven by the growing prevalence of type II inflammatory disorders including EoE, advances in the treatment procedures, and intense competition among players for the first FDA approved drug to have a first-mover advantage. Huge unmet in EoE is also favoring the growth of the eosinophilic esophagitis drug industry. Diagnosis criteria of EoE are imperfect, as it is derived by expert opinions (with consensus between gastroenterologists, allergists, and pathologists), rather than being evidence-based. Currently, histologic criteria for EoE is not clear and it requires repeated tissue assessment to confirm disease onset, as there is no coherence between disease activity with patient symptoms.

The global eosinophilic esophagitis drug industry is fragmented based on the product, diagnosis, treatment, and region. In terms of product, the market is segmented into off-label drugs, Budesonide Oral Suspension, fluticasone ODT, Mepolizumab, Reslizumab, Benralizumab, Dupilunab, Omalizumab, QAX576, AKOO2, and losartan. Based on the diagnosis, the market for eosinophilic esophagitis is further bifurcated into upper endoscopy, esophagus biopsy, blood tests, others. Based on treatment, the eosinophilic esophagitis market is further bifurcated into dietary therapy, medication, dilation, others.

Segment Highlights
  • The Dupilunab segment of the eosinophilic esophagitis drug industry accounted for the largest revenue share in 2020 as the majority of rare disease lies within neurology therapy area. Dupilunab market held over 25% of the global share in 2020.
  • Based on treatment, the dietary therapy segment for the eosinophilic esophagitis drug industry is projected to constitute almost half of the market in 2028. This can be attributed to current treatment based on a strict dietary regimen owing to the onset of EoE following food allergies.
  • North America region is dominating the global eosinophilic esophagitis market, holding almost one-third of the market share throughout forecast period. No FDA approved drugs and huge unmet medical needs are factors responsible for such growth.
  • The players including Bristol-Myers Squibb, Takeda (Shire), AstraZeneca, and Regeneron pharmaceuticals together hold a significant market share of the global market in 2020.
List of Key Players
  • Regeneron Pharmaceuticals
  • Adare Pharmaceuticals, Inc.
  • Bristol-Myers Squibb
  • Takeda (Shire)
  • DBV Technologies
  • Falk Pharma GmbH
  • Allakos, Inc.
  • Arena Pharmaceuticals
  • Ception Therapeutics
  • Others
The analyst has segmented the eosinophilic esophagitis drug market report on the basis of product, diagnosis, treatment, and region:

Eosinophilic Esophagitis Drug, Product Outlook (Revenue-USD Million, 2016-2028)
  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab
  • QAX576
  • AKOO2
  • Losartan
Eosinophilic Esophagitis Drug, Diagnosis Outlook (Revenue-USD Million, 2016-2028)
  • Upper Endoscopy
  • Esophagus Biopsy
  • Blood Tests
  • Others
Eosinophilic Esophagitis Drug, Treatment Outlook (Revenue-USD Million, 2016-2028)
  • Dietary Therapy
  • Medication
  • Dilation
  • Others
Eosinophilic Esophagitis Drug, Regional Outlook (Revenue-USD Million, 2016-2028)
  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Spain
  • Netherlands
  • Austria
  • Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Central & South America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allakos Inc.
  • Arena Pharmaceuticals
  • Bristol-Myers Squibb
  • Ception Therapeutics
  • DBV Technologies
  • Dr. Falk Pharma GmbH
1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary
2.1. Market Highlights

3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources

4. Eosinophilic Esophagitis Drug Market Insights
4.1. Eosinophilic Esophagitis Drug - Industry snapshot
4.2. Eosinophilic Esophagitis Drug Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Strong Drug Pipeline
4.2.1.2. Aging Population
4.2.2. Restraints and Challenges
4.2.2.1. Adverse Reactions
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Eosinophilic Esophagitis Drug Market Industry trends

5. Eosinophilic Esophagitis Drug Market Assessment by Product
5.1. Key Findings
5.2. Introduction
5.2.1. Global Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
5.3. Off-Label Drugs
5.3.1. Global Eosinophilic Esophagitis Drug Market, by Off-Label Drugs, by Region, 2016-2028 (USD Million)
5.4. Budesonide Oral Suspension
5.4.1. Global Eosinophilic Esophagitis Drug Market, by Budesonide Oral Suspension, by Region, 2016-2028 (USD Million)
5.5. Fluticasone ODT
5.5.1. Global Eosinophilic Esophagitis Drug Market, by Fluticasone ODT, by Region, 2016-2028 (USD Million)
5.6. Mepolizumab
5.6.1. Global Eosinophilic Esophagitis Drug Market, by Mepolizumab, by Region, 2016-2028 (USD Million)
5.7. Reslizumab
5.7.1. Global Eosinophilic Esophagitis Drug Market, by Reslizumab, by Region, 2016-2028 (USD Million)
5.8. Benralizumab
5.8.1. Global Eosinophilic Esophagitis Drug Market, by Benralizumab, by Region, 2016-2028 (USD Million)
5.9. Dupilunab
5.9.1. Global Eosinophilic Esophagitis Drug Market, by Dupilunab, by Region, 2016-2028 (USD Million)
5.10. Omalizumab
5.10.1. Global Eosinophilic Esophagitis Drug Market, by Omalizumab, by Region, 2016-2028 (USD Million)
5.11. QAX576
5.11.1. Global Eosinophilic Esophagitis Drug Market, by QAX576, by Region, 2016-2028 (USD Million)
5.12. AKOO2
5.12.1. Global Eosinophilic Esophagitis Drug Market, by AKOO2, by Region, 2016-2028 (USD Million)
5.13. Losartan
5.13.1. Global Eosinophilic Esophagitis Drug Market, by Losartan, by Region, 2016-2028 (USD Million)

6. Global Eosinophilic Esophagitis Drug Market, by Diagnosis
6.1. Key Findings
6.2. Introduction
6.2.1. Global Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
6.3. Upper Endoscopy
6.3.1. Global Eosinophilic Esophagitis Drug Market, by Upper Endoscopy, By Region, 2016-2028 (USD Million)
6.4. Esophagus Biopsy
6.4.1. Global Eosinophilic Esophagitis Drug Market, by Esophagus Biopsy, by Region, 2016-2028 (USD Million)
6.5. Blood Tests
6.5.1. Global Eosinophilic Esophagitis Drug Market, by Blood Tests, by Region, 2016-2028 (USD Million)
6.6. Others
6.6.1. Global Eosinophilic Esophagitis Drug Market, by Others by Region, 2016-2028 (USD Million)

7. Eosinophilic Esophagitis Drug Market Assessment by Treatment
7.1. Key Findings
7.2. Introduction
7.2.1. Global Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
7.3. Dietary Therapy
7.3.1. Global Eosinophilic Esophagitis Drug Market, by Dietary Therapy, by Region, 2016-2028 (USD Million)
7.4. Medication
7.4.1. Global Eosinophilic Esophagitis Drug Market, by Medication, by Region, 2016-2028 (USD Million)
7.5. Dilation
7.5.1. Global Eosinophilic Esophagitis Drug Market, by Dilation, by Region, 2016-2028 (USD Million)
7.6. Others
7.6.1. Global Eosinophilic Esophagitis Drug Market, by Others, by Region, 2016-2028 (USD Million)

8. Eosinophilic Esophagitis Drug Market Assessment by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Eosinophilic Esophagitis Drug Market Assessment, By Geography, 2016-2028 (USD Million)
8.3. Eosinophilic Esophagitis Drug Market - North America
8.3.1. North America: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.3.2. North America: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.3.3. North America: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.3.4. Eosinophilic Esophagitis Drug Market - U.S.
8.3.4.1. U.S.: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.3.4.2. U.S.: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.3.4.3. U.S.: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.3.5. Eosinophilic Esophagitis Drug Market - Canada
8.3.5.1. Canada: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.3.5.2. Canada: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.3.5.3. Canada: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4. Eosinophilic Esophagitis Drug Market - Europe
8.4.1. Europe: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.2. Europe.: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.3. Europe: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.4. Eosinophilic Esophagitis Drug Market - UK
8.4.4.1. UK: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.4.2. UK: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.4.3. UK: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.5. Eosinophilic Esophagitis Drug Market - France
8.4.5.1. France: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.5.2. France: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.5.3. France: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.6. Eosinophilic Esophagitis Drug Market - Germany
8.4.6.1. Germany: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.6.2. Germany: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.6.3. Germany: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.7. Eosinophilic Esophagitis Drug Market - Italy
8.4.7.1. Italy: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.7.2. Italy: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.7.3. Italy: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.8. Eosinophilic Esophagitis Drug Market - Spain
8.4.8.1. Spain: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.8.2. Spain: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.8.3. Spain: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.9. Eosinophilic Esophagitis Drug Market - Netherlands
8.4.9.1. Netherlands: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.9.2. Netherlands: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.9.3. Netherlands: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.4.10. Eosinophilic Esophagitis Drug Market - Austria
8.4.10.1. Austria: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.4.10.2. Austria: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.4.10.3. Austria: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5. Eosinophilic Esophagitis Drug Market - Asia-Pacific
8.5.1. Asia Pacific: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.2. Asia Pacific: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.3. Asia Pacific: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.4. Eosinophilic Esophagitis Drug Market - China
8.5.4.1. China: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.4.2. China: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.4.3. China: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.5. Eosinophilic Esophagitis Drug Market - India
8.5.5.1. India: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.5.2. India: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.5.3. India: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.6. Eosinophilic Esophagitis Drug Market - Malaysia
8.5.6.1. Malaysia: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.6.2. Malaysia: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.6.3. Malaysia: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.7. Eosinophilic Esophagitis Drug Market - Japan
8.5.7.1. Japan: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.7.2. Japan: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.7.3. Japan: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.8. Eosinophilic Esophagitis Drug Market - Indonesia
8.5.8.1. Indonesia: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.8.2. Indonesia: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.8.3. Indonesia: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.5.9. Eosinophilic Esophagitis Drug Market - South Korea
8.5.9.1. South Korea: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.5.9.2. South Korea: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.5.9.3. South Korea: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.6. Eosinophilic Esophagitis Drug Market - Middle East & Africa
8.6.1. Middle East & Africa: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.6.2. Middle East & Africa: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.6.3. Middle East & Africa: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.6.4. Eosinophilic Esophagitis Drug Market - Saudi Arabia
8.6.4.1. Saudi Arabia: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.6.4.2. Saudi Arabia: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.6.4.3. Saudi Arabia: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.6.5. Eosinophilic Esophagitis Drug Market - UAE
8.6.5.1. UAE: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.6.5.2. UAE: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.6.5.3. UAE: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.6.6. Eosinophilic Esophagitis Drug Market - Israel
8.6.6.1. Israel: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.6.6.2. Israel: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.6.6.3. Israel: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.6.7. Eosinophilic Esophagitis Drug Market - South Africa
8.6.7.1. South Africa: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.6.7.2. South Africa: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.6.7.3. South Africa: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.7. Eosinophilic Esophagitis Drug Market - Latin America
8.7.1. Latin America: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.7.2. Latin America: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.7.3. Latin America: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.7.4. Eosinophilic Esophagitis Drug Market - Mexico
8.7.4.1. Mexico: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.7.4.2. Mexico: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.7.4.3. Mexico: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.7.5. Eosinophilic Esophagitis Drug Market - Brazil
8.7.5.1. Brazil: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.7.5.2. Brazil: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.7.5.3. Brazil: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)
8.7.6. Eosinophilic Esophagitis Drug Market - Argentina
8.7.6.1. Argentina: Eosinophilic Esophagitis Drug Market, By Product, 2016-2028 (USD Million)
8.7.6.2. Argentina: Eosinophilic Esophagitis Drug Market, By Diagnosis, 2016-2028 (USD Million)
8.7.6.3. Argentina: Eosinophilic Esophagitis Drug Market, By Treatment, 2016-2028 (USD Million)

9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisition
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles
10.1. Regeneron Pharmaceuticals
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product/Services Benchmarking
10.1.4. Recent Developments
10.2. Bristol-Myers Squibb, Takeda (Shire)
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product/Services Benchmarking
10.2.4. Recent Developments
10.3. DBV Technologies
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product/Services Benchmarking
10.3.4. Recent Developments
10.4. AstraZeneca
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product/Services Benchmarking
10.4.4. Recent Developments
10.5. Dr. Falk Pharma GmbH
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product/Services Benchmarking
10.5.4. Recent Developments
10.6. Allakos, Inc.
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product/Services Benchmarking
10.6.4. Recent Developments
10.7. Arena Pharmaceuticals
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product/Services Benchmarking
10.7.4. Recent Developments
10.8. Ception Therapeutics
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product/Services Benchmarking
10.8.4. Recent Developments
Note: Product cover images may vary from those shown
  • Regeneron Pharmaceuticals
  • Adare Pharmaceuticals Inc.
  • Bristol-Myers Squibb
  • Takeda (Shire)
  • DBV Technologies
  • Dr. Falk Pharma GmbH
  • Allakos Inc.
  • Arena Pharmaceuticals
  • Ception Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll